Tongtong Zhang

Tongtong Zhang

Auto-generated profile, based on publicly available information

Tongtong Zhang

Department of Urology, First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Street, Nanjing, Jiangsu Province, 210029, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2020 in Nature Reviews Urology
Verified
Journal Article
Open access
PDF file
SWShangqian Wang
Shangqian Wang
XZXiang Zhou
Xiang Zhou
TZTongtong Zhang
Tongtong Zhang
ZWZengjun Wang
Zengjun Wang
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2, which invades a cell through binding to the ACE2 receptor and TMPRSS2 priming. Patients with severe disease predominantly present with pneumonia-related symptoms. However, evidence suggests that COVID-19 infection also has implications for the urogenital tract. Thus, urogenital organs should be considered when treating COVID-19.

1 May 2021 in Chemosphere
Verified
Journal Article
Closed access
ZWZhongyuan Wang
Zhongyuan Wang
TZTongtong Zhang
Tongtong Zhang
JWJiajin Wu
Jiajin Wu
XWXiyi Wei
Xiyi Wei
AXAiming Xu
Aiming Xu
ZWZengjun Wang
Zengjun Wang

1 June 2020 in Science of The Total Environment
Verified
Journal Article
Closed access
TZTongtong Zhang
Tongtong Zhang
XZXiang Zhou
Xiang Zhou
AXAiming Xu
Aiming Xu
YTYe Tian
Ye Tian
YWYuhao Wang
Yuhao Wang
ZWZengjun Wang
Zengjun Wang

1 January 2017 in Chinese Journal of Cancer Research
Verified
Journal Article
Open access
JWJiani Wang
Jiani Wang
QLQing Li
Qing Li
BXBinghe Xu
Binghe Xu
TZTongtong Zhang
Tongtong Zhang
SCShanshan Chen
Shanshan Chen
YLYang Luo
Yang Luo
Chemotherapy with paclitaxel is associated with significant neurotoxicity that may offset patients' quality of life and therapeutic benefits. This prospective, non-randomized control study evaluated the efficacy and safety of an antidepressant drug, duloxetine, at 30 or 60 mg/d, in the treatment of paclitaxel-induced peripheral neuropathy (PIPN) in Chinese breast cancer patients. A total of 102 patients with a median age of 50 (range, 25-60) years, treated in the Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, between November 2014 and January 2017 were finally enrolled. Stratified by baseline characteristics, the patients were classified into two groups, receiving either duloxetine or alternative anti-neurotoxicity drugs. During the course of the paclitaxel regimen, the eligibility criteria included sensory neuropathy, as evaluated by the National Cancer Institute-Common Toxicity Criteria for Adverse Events. The treatment consisted of receiving 30 mg duloxetine (for the first 4 weeks) and 60 mg duloxetine for an additional 8 weeks, or any other anti-neurotoxicity drug daily during the same crossover period. The improvement associated with PIPN from the patient's perspective were assessed by the Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) Scales, which contained questions scored from 0 to 4 (0, not at all; 4, very much; total score range, 0-44). Duloxetine was more effective in decreasing PIPN (odds ratio=5.426; 95% confidence interval, 1.898-15.514; P=0.002). Between duloxetine group and control group, the median (25th-75th percentiles) decreasing difference in the FACT-Tax pain score was 4 (2-6) vs. 1 (0-4) (P=0.005). Duloxetine is a promising and safe option with tolerable toxicity at a dose of 60 mg/d for Chinese breast cancer patients with PIPN. Non-neuropathy adverse events were mild and similar in both groups. The major toxicities of duloxetine included nausea, constipation, somnolence, dizziness and distention of the eyes. Further examination of the benefits of duloxetine in the prevention of PIPN is required.

1 April 2021 in Reproductive Toxicology
Verified
Journal Article
Closed access
XRXiaohan Ren
Xiaohan Ren
XZXu Zhang
Xu Zhang
XCXinglin Chen
Xinglin Chen
TZTongtong Zhang
Tongtong Zhang
GLGuangyao Li
Guangyao Li
SWShangqian Wang
Shangqian Wang